Cilostazol in patients with ischemic stroke

Zaid A. Al-Qudah; Ameer E. Hassan; Adnan I. Qureshi

doi:10.1517/14656566.2011.576248

Cilostazol in patients with ischemic stroke

Zaid A. Al-Qudah, Ameer E. Hassan, Adnan I. Qureshi

Neurology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding.Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention.Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized.Pharmacology and mechanism of action are also discussed.Expert opinion: Cilostazol is a safe and effective medication.It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.

Original language	English (US)
Pages (from-to)	1305-1315
Number of pages	11
Journal	Expert Opinion on Pharmacotherapy
Volume	12
Issue number	8
DOIs	https://doi.org/10.1517/14656566.2011.576248
State	Published - Jun 2011

Bibliographical note

Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.

Keywords

acute ischemic stroke
cilostazol
neurointerventional procedures

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1517/14656566.2011.576248

OpenUrl availability

Full text

Cite this

@article{0c21f54a0da14ed9946b894572cc8789,

title = "Cilostazol in patients with ischemic stroke",

abstract = "Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding.Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention.Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized.Pharmacology and mechanism of action are also discussed.Expert opinion: Cilostazol is a safe and effective medication.It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.",

keywords = "acute ischemic stroke, cilostazol, neurointerventional procedures",

author = "Al-Qudah, {Zaid A.} and Hassan, {Ameer E.} and Qureshi, {Adnan I.}",

year = "2011",

month = jun,

doi = "10.1517/14656566.2011.576248",

language = "English (US)",

volume = "12",

pages = "1305--1315",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Cilostazol in patients with ischemic stroke

AU - Al-Qudah, Zaid A.

AU - Hassan, Ameer E.

AU - Qureshi, Adnan I.

PY - 2011/6

Y1 - 2011/6

N2 - Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding.Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention.Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized.Pharmacology and mechanism of action are also discussed.Expert opinion: Cilostazol is a safe and effective medication.It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.

AB - Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding.Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention.Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized.Pharmacology and mechanism of action are also discussed.Expert opinion: Cilostazol is a safe and effective medication.It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.

KW - acute ischemic stroke

KW - cilostazol

KW - neurointerventional procedures

UR - http://www.scopus.com/inward/record.url?scp=79955796312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955796312&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.576248

DO - 10.1517/14656566.2011.576248

M3 - Article

C2 - 21548722

AN - SCOPUS:79955796312

SN - 1465-6566

VL - 12

SP - 1305

EP - 1315

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 8

ER -

Cilostazol in patients with ischemic stroke

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this